Vaxcyte Stock Based Compensation from 2010 to 2025

PCVX Stock

USD 88.32 3.12 3.41%

Vaxcyte Stock Based Compensation yearly trend continues to be fairly stable with very little volatility. Stock Based Compensation is likely to outpace its year average in 2025. Stock Based Compensation is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. View All Fundamentals

Stock Based Compensation

First Reported

2019-03-31

Previous Quarter

21.6 M

Current Value

21.3 M

Quarterly Volatility

6.9 M

Covid

Check Vaxcyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vaxcyte's main balance sheet or income statement drivers, such as Interest Income of 76 M, Interest Expense of 0.0 or Selling General Administrative of 73.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 4.65. Vaxcyte financial statements analysis is a perfect complement when working with Vaxcyte Valuation or Volatility modules.

Check out the analysis of Vaxcyte Correlation against competitors.

For more information on how to buy Vaxcyte Stock please use our How to Invest in Vaxcyte guide.

Latest Vaxcyte's Stock Based Compensation Growth Pattern

Below is the plot of the Stock Based Compensation of Vaxcyte over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. Vaxcyte's Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vaxcyte's overall financial position and show how it may be relating to other accounts over time.

Stock Based Compensation

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Stock Based Compensation

Timeline

Vaxcyte Stock Based Compensation Regression Statistics

	Arithmetic Mean	12,841,364
	Geometric Mean	65,153
	Coefficient Of Variation	168.90
	Mean Deviation	16,999,531
	Median	749,000
	Standard Deviation	21,688,603
	Sample Variance	470.4T
	Range	58.9M
	R-Value	0.80
	Mean Square Error	184.1T
	R-Squared	0.63
	Significance	0.0002
	Slope	3,629,249
	Total Sum of Squares	7055.9T

Vaxcyte Stock Based Compensation History

	2025	58.9 M
	2024	56.1 M
	2023	48.8 M
	2022	23.6 M
	2021	10.7 M
	2020	5.4 M
	2019	1.2 M

Other Fundumenentals of Vaxcyte

Stock Based Compensation To Revenue

Vaxcyte Stock Based Compensation component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Long Term Debt	Long Term Debt Total	Capital Surpluse	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Debt	Net Invested Capital	Capital Stock	Net Working Capital	Short Term Debt	Net Receivables	Deferred Long Term Liab
Total Assets		1.0	0.98	-0.98	0.59	-0.74	-0.74	0.87	0.63	1.0	0.97	0.88	-0.69	-0.7	1.0	0.97	0.99	0.68	0.96	0.85
Total Stockholder Equity	1.0		0.99	-0.97	0.59	-0.71	-0.71	0.88	0.57	1.0	0.98	0.88	-0.67	-0.72	1.0	0.98	0.99	0.7	0.95	0.86
Net Tangible Assets	0.98	0.99		-0.96	0.63	-0.76	-0.76	0.92	0.55	0.99	0.99	0.9	-0.72	-0.8	0.99	0.99	1.0	0.78	0.9	0.88
Retained Earnings	-0.98	-0.97	-0.96		-0.59	0.77	0.77	-0.88	-0.68	-0.98	-0.97	-0.9	0.74	0.67	-0.98	-0.97	-0.97	-0.7	-0.95	-0.89
Accounts Payable	0.59	0.59	0.63	-0.59		-0.73	-0.73	0.77	0.42	0.62	0.69	0.43	-0.72	-0.62	0.61	0.69	0.61	0.78	0.48	0.45
Long Term Debt	-0.74	-0.71	-0.76	0.77	-0.73		1.0	-0.88	-0.67	-0.75	-0.82	-0.77	1.0	0.65	-0.75	-0.82	-0.74	-0.84	-0.65	-0.76
Long Term Debt Total	-0.74	-0.71	-0.76	0.77	-0.73	1.0		-0.88	-0.67	-0.75	-0.82	-0.77	1.0	0.65	-0.75	-0.82	-0.74	-0.84	-0.65	-0.76
Capital Surpluse	0.87	0.88	0.92	-0.88	0.77	-0.88	-0.88		0.49	0.89	0.96	0.9	-0.85	-0.73	0.9	0.96	0.88	0.94	0.79	0.88
Total Liab	0.63	0.57	0.55	-0.68	0.42	-0.67	-0.67	0.49		0.62	0.58	0.51	-0.65	-0.31	0.6	0.58	0.59	0.33	0.65	0.54
Total Current Assets	1.0	1.0	0.99	-0.98	0.62	-0.75	-0.75	0.89	0.62		0.98	0.88	-0.71	-0.76	1.0	0.98	1.0	0.72	0.93	0.86
Common Stock	0.97	0.98	0.99	-0.97	0.69	-0.82	-0.82	0.96	0.58	0.98		0.92	-0.79	-0.73	0.98	1.0	0.97	0.82	0.92	0.89
Property Plant Equipment	0.88	0.88	0.9	-0.9	0.43	-0.77	-0.77	0.9	0.51	0.88	0.92		-0.74	-0.61	0.89	0.92	0.88	0.78	0.85	0.98
Current Deferred Revenue	-0.69	-0.67	-0.72	0.74	-0.72	1.0	1.0	-0.85	-0.65	-0.71	-0.79	-0.74		0.65	-0.7	-0.79	-0.7	-0.84	-0.6	-0.74
Net Debt	-0.7	-0.72	-0.8	0.67	-0.62	0.65	0.65	-0.73	-0.31	-0.76	-0.73	-0.61	0.65		-0.73	-0.73	-0.78	-0.78	-0.47	-0.64
Net Invested Capital	1.0	1.0	0.99	-0.98	0.61	-0.75	-0.75	0.9	0.6	1.0	0.98	0.89	-0.7	-0.73		0.98	1.0	0.72	0.94	0.87
Capital Stock	0.97	0.98	0.99	-0.97	0.69	-0.82	-0.82	0.96	0.58	0.98	1.0	0.92	-0.79	-0.73	0.98		0.97	0.82	0.92	0.89
Net Working Capital	0.99	0.99	1.0	-0.97	0.61	-0.74	-0.74	0.88	0.59	1.0	0.97	0.88	-0.7	-0.78	1.0	0.97		0.72	0.92	0.86
Short Term Debt	0.68	0.7	0.78	-0.7	0.78	-0.84	-0.84	0.94	0.33	0.72	0.82	0.78	-0.84	-0.78	0.72	0.82	0.72		0.54	0.8
Net Receivables	0.96	0.95	0.9	-0.95	0.48	-0.65	-0.65	0.79	0.65	0.93	0.92	0.85	-0.6	-0.47	0.94	0.92	0.92	0.54		0.81
Deferred Long Term Liab	0.85	0.86	0.88	-0.89	0.45	-0.76	-0.76	0.88	0.54	0.86	0.89	0.98	-0.74	-0.64	0.87	0.89	0.86	0.8	0.81

Click cells to compare fundamentals

About Vaxcyte Financial Statements

Vaxcyte investors use historical fundamental indicators, such as Vaxcyte's Stock Based Compensation, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vaxcyte. Please read more on our technical analysis and fundamental analysis pages.

		Last Reported	Projected for Next Year
	Stock Based Compensation	56.1 M	58.9 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

EBR	Centrais Electricas Brasileiras
HE	Hawaiian Electric Industries
VFC	VF Corporation

Additional Tools for Vaxcyte Stock Analysis

When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Vaxcyte Stock Based Compensation from 2010 to 2025

Latest Vaxcyte's Stock Based Compensation Growth Pattern

Vaxcyte Stock Based Compensation Regression Statistics

Vaxcyte Stock Based Compensation History

Other Fundumenentals of Vaxcyte

Vaxcyte Stock Based Compensation component correlations

About Vaxcyte Financial Statements

Also Currently Popular

Additional Tools for Vaxcyte Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY